Baseline signatures associated with clinical, virologic, and immunologic outcomes in patients with mild to moderate COVID-19
Ontology highlight
ABSTRACT: The vast majority of SARS-CoV-2 infections are uncomplicated and do not require hospitalization, but these infections contribute to ongoing transmission. There remains a critical need to identify host immune biomarkers predictive of virologic and clinical outcomes in planning future treatment studies of COVID-19. We recently completed a randomized clinical trial of Pegylated PegIinterferon Lambda for treatment of SARS-CoV-2 infected patients conducted in the Stanford COVID-19 CTRU. Leveraging longitudinal samples and data from this trial, we define early immunebaseline and infection-induced signatures that predict the duration of viral shedding, resolution of symptoms, and immunologic memory.
ORGANISM(S): Homo sapiens
PROVIDER: GSE178967 | GEO | 2021/10/01
REPOSITORIES: GEO
ACCESS DATA